Abstract: A method for treating schizophrenia and a method and composition for potentiating the beneficial effects and reducing the side effects of neuroleptic drugs. Schizophrenia is treated with a GABA-like compound such as Lioresal. Neuroleptic drugs are potentiated by coadministering to a schizophrenic a neuroleptic drug and a GABA-like drug such as Lioresal.

Abstract: There is disclosed a topical antibacterial composition and method for topical antibiotic treatment. The method involves contacting the skin of a human or animal with an effective amount of a composition containing an antibiotic of the erythromycin family and 2-pyrrolidone or an N-lower alkyl-2-pyrrolidone. The preferred use of the foregoing composition and method is in the treatment of acne.

Abstract: A method for treating schizophrenia and a method and composition for potentiating the beneficial effects and reducing the side effects of neuroleptic drugs. Schizophrenia is treated with a GABA-like compound such as Lioresal. Neuroleptic drugs are potentiated by coadministering to a schizophrenic a neuroleptic drug and a GABA-like drug such as Lioresal.

Abstract: There is disclosed an improved method for topically administering a physiologically active agent to a human or animal by dissolving an effective amount of the agent in a carrier containing suitable amounts of 1-alkyl substituted-azacyclopentan-2-one, as defined herein, and contacting the skin or other membranes of the human or animal with the resulting composition, whereby penetration of the skin or membranes is enhanced.

Abstract: Novel compounds having the structural formula ##STR1## where B is NR, O, S, ##STR2## or --CH.sub.2 ; (M).sub.n is a saturated or unsaturated aliphatic hydrocarbon chain; X is NR, O or S; A is SO.sub.2 R, CN, NO.sub.2 or H; Y is NR.sub.2, N.sub.3, halogen or SH; R is H and/or a lower alkyl group; D is N.sub.3 or halogen and n is 1-12.

Abstract: A method for treating schizophrenia and a method and composition for potentiating the beneficial effects and reducing the side effects of neuroleptic drugs. Schizophrenia is treated with a GABA-like compound such as Lioresal. Neuroleptic drugs are potentiated by coadministering to a schizophrenic a neuroleptic drug and a GABA-like drug such as Lioresal.

Abstract: There is disclosed a composition and method for topically administering griseofulvin to a human or animal in a manner such that a high degree of epidermal, especially stratum corneum, retention of griseofulvin is attained, by contacting the skin of a human or animal with an effective amount of a therapeutic composition containing griseofulvin in a vehicle system comprising 2-pyrrolidone and N-methyl-2-pyrrolidone in a ratio ranging between about 1:4 and about 4:1, said composition containing at least about 10% by weight of said vehicle system.

Abstract: A composition and method for treating psoriasis in humans comprising the administration to a human suffering from psoriasis of a beta-adrenergic receptor stimulating compound such as isoproterenol.

Abstract: Novel prostaglandin dehydrogenase inhibiting agents having the structural formula ##STR1## X is hydroxyl, dialkylaminomethyl, lower alkyl, lower alkoxy, aryl, substituted aryl, halogen, cyano, nitro, trihaloalkyl, --NR.sub.1 R.sub.2 or --NHCOR.sub.1 where R.sub.1 and R.sub.2 are hydrogen, lower alkyl or NH.sub.2 and n is 0-5.

Abstract: An improved method of synthesis of trans-2-phenylcyclopropylamine wherein the improvement comprises isomerizing an intermediate ester, namely, cis,trans-ethyl-2-phenylcyclopropanecarboxylate, by reacting said ester with anhydrous sodium ethoxide, to form a reaction product containing not more than about 5 percent cis ester and further reacting said resultant product to form trans-2-phenylcyclopropylamine.

Abstract: Novel prostaglandin dehydrogenase inhibiting agents having the structural formula ##STR1## M is H or a pharmaceutically acceptable salt, X is hydrogen, dialkylaminomethyl, lower alkyl, lower alkoxy, aryl, substituted aryl, halogen, cyano, nitro, trihaloalkyl, --NR.sub.1 R.sub.2 or --NHCOR.sub.1 where R.sub.1 and R.sub.2 are hydrogen, lower alkyl or NH.sub.2 and n is 0-5.

Abstract: A method for binding biologically active compounds to carriers comprising reacting an asymmetric bifunctional linking compound having at least one phenyl azide moiety and at least one s-triazine moiety with a carrier in the presence of light to form a carrier bound to the linking compound through the phenyl azide moiety, and reacting said carrier bound to the linking compound with a biologically active compound under reaction conditions sufficient to bind the biologically active compound to the linking compound through the s-triazine moiety.

Abstract: The invention relates to compounds represented by the following general structure: ##STR1## and their method of making. These compounds are therapeutically useful as anti-inflammatory agents and operate as inhibitors of prostaglandin synthetase and also as prostaglandin receptor blockers.

Abstract: There is disclosed an improved method for topically administering a physiologically active agent to a human or animal by dissolving an effective amount of the agent in a carrier containing suitable amounts of 1-substituted azacyclopentan-2-one, as defined herein, and contacting the skin or other membranes of the human or animal with the resulting composition, whereby penetration of the skin or membranes is enhanced.

Abstract: Methods of temporarily alleviating symptoms of hypersomnia or mental fatigue or drowsiness or temporarily suppressing appetite by administering to a human or animal having one or more of the aforementioned symptoms an effective amount of piperoxan together with a suitable pharmaceutical carrier. Piperoxan is also useful for potentiating the effects of anti-depressant drugs.

Abstract: There is disclosed an improved method for topically administering a physiologically active agent to a human or animal by dissolving an effective amount of the agent in a carrier containing suitable amounts of N-bis-azacyclopentan-2-onyl alkanes, as defined herein, and contacting the skin or other membranes of the human or animal with the resulting composition, whereby penetration of the skin or membranes is enhanced.

Abstract: There is disclosed an improved method for topically administering a physiologically active agent to a human or animal by dissolving an effective amount of the agent in a carrier containing suitable amounts of 1-substituted-azacycloheptan-2-one, as defined herein, and contacting the skin or other membranes of the human or animal with the resulting composition, whereby penetration of the skin or membranes is enhanced.

Abstract: A method for stimulating the production of thyroid stimulating hormone (TSH) and enhancing thyroid function in animals comprising administering to an animal having low thyroid function an effective amount of a cyclic nucleotide derivative having the structural formula ##SPC1##Wherein R is selected from the group consisting of amino, thiomethyl and azido and pharmaceutically acceptable salts thereof.

Abstract: Compounds having the structural formula ##SPC1##Wherein X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##EQU1## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##EQU2## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different, T is 0 or 1 and n is 0-5; and pharmaceutically acceptable salts thereof.

Abstract: A method for treating schizophrenia and a method and composition for potentiating the beneficial effects and reducing the side effects of neuroleptic drugs. Schizophrenia is treated with a GABA-like compound such as Lioresal. Neuroleptic drugs are potentiated by coadministering to a schizophrenic a neuroleptic drug and a GABA-like drug such as Lioresal.